MX2012000766A - Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. - Google Patents

Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.

Info

Publication number
MX2012000766A
MX2012000766A MX2012000766A MX2012000766A MX2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A
Authority
MX
Mexico
Prior art keywords
compound
erythropoietin production
prolyl hydroxylase
action
hydroxylase inhibitor
Prior art date
Application number
MX2012000766A
Other languages
English (en)
Inventor
Takashi Ito
Masahiro Yokota
Kazuhito Ueyama
Ikuo Mitani
Yosuke Ogoshi
Takuya Matsui
Masakazu Terashita
Dai Motoda
Takahiro Hotta
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2012000766A publication Critical patent/MX2012000766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)

Abstract

La presente invención provee un compuesto de triazolopiridina que tiene una acción inhibidora de prolil hidroxilasa y la capacidad de inducir la producción de eritropoyetina; la presente invención se refiere a un compuesto representado por la siguiente fórmula [I]: (ver fórmula (I)) donde cada símbolo es como se definió en la especificación, o su sal aceptable farmacéuticamente, o un solvato del mismo, como también un inhibidor de la prolil hidroxilasa o un agente que induce la producción de eritropoyetina que contiene el compuesto; el compuesto de la presente invención muestra una acción inhibidora de prolil hidroxilasa y la capacidad de inducir la producción de eritropoyetina y es útil como agente profiláctico o terapéutico para varias enfermedades y patologías (trastornos) originados por la producción disminuida de la eritropoyetina.
MX2012000766A 2009-07-17 2010-07-16 Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. MX2012000766A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17
US27312709P 2009-07-30 2009-07-30
PCT/JP2010/062037 WO2011007856A1 (ja) 2009-07-17 2010-07-16 トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用

Publications (1)

Publication Number Publication Date
MX2012000766A true MX2012000766A (es) 2012-02-08

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000766A MX2012000766A (es) 2009-07-17 2010-07-16 Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.

Country Status (29)

Country Link
US (3) US8283465B2 (es)
EP (3) EP2455381B9 (es)
JP (9) JP5021797B2 (es)
KR (4) KR20180042443A (es)
CN (1) CN102471337B (es)
AR (1) AR077417A1 (es)
AU (1) AU2010271732B2 (es)
BR (1) BR112012001157A2 (es)
CA (1) CA2768505C (es)
CO (1) CO6430426A2 (es)
DK (1) DK2455381T5 (es)
ES (1) ES2477968T3 (es)
HK (1) HK1168346A1 (es)
HR (1) HRP20140705T1 (es)
IL (1) IL217541A (es)
ME (1) ME01858B (es)
MX (1) MX2012000766A (es)
MY (1) MY160814A (es)
NZ (1) NZ598242A (es)
PE (1) PE20120629A1 (es)
PL (1) PL2455381T3 (es)
PT (1) PT2455381E (es)
RS (1) RS53499B1 (es)
RU (1) RU2538963C2 (es)
SG (1) SG178049A1 (es)
SI (1) SI2455381T1 (es)
SM (1) SMT201500122B (es)
TW (1) TWI485150B (es)
WO (1) WO2011007856A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178049A1 (en) * 2009-07-17 2012-03-29 Japan Tobacco Inc Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CA2896437C (en) * 2012-11-26 2021-01-19 Takaaki Abe Erythropoietin expression promoter
TWI598339B (zh) 2012-12-24 2017-09-11 卡地拉保健有限公司 新穎喹啉酮衍生物
ES2974273T3 (es) 2013-06-13 2024-06-26 Akebia Therapeutics Inc Composiciones y métodos para tratar la anemia
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
SG11201602572YA (en) 2013-10-03 2016-04-28 Kura Oncology Inc Inhibitors of erk and methods of use
CN105384687B (zh) 2014-09-02 2018-05-01 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
JP6814134B2 (ja) * 2015-05-28 2021-01-13 日本たばこ産業株式会社 糖尿病性腎症を治療又は予防する方法
MX2019006083A (es) * 2016-11-25 2019-07-10 Japan Tobacco Inc Metodo para la produccion de compuesto de triazolopiridina.
EP3613742B1 (en) 2017-05-09 2022-12-07 Kind Pharmaceutical Indolizine derivatives and application thereof in medicine
WO2019069973A1 (ja) * 2017-10-04 2019-04-11 日本たばこ産業株式会社 含窒素ヘテロアリール化合物およびその医薬用途
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
US20210206765A1 (en) * 2018-09-13 2021-07-08 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法
JPWO2021182490A1 (es) * 2020-03-11 2021-09-16
JP7504822B2 (ja) 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN116496269A (zh) * 2021-12-02 2023-07-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
TW202412778A (zh) * 2022-09-19 2024-04-01 大陸商蘇中藥業集團股份有限公司 一種脯氨醯羥化酶抑制劑及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
EP1435952A1 (en) * 2001-10-08 2004-07-14 F. Hoffmann-La Roche Ag 8-amino- 1,2,4]triazolo 1,5-a]pyridine-6-carboxylic acid amide
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
RU2007106180A (ru) * 2004-08-05 2008-09-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные индола, индазола или индолина
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
PE20080209A1 (es) * 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
ES2705587T3 (es) * 2006-06-26 2019-03-26 Akebia Therapeutics Inc Inhibidores de prolil hidroxilasa y métodos de uso
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
CL2008000066A1 (es) * 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
AU2008241483B2 (en) 2007-04-18 2011-03-24 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008137084A2 (en) 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
NZ585701A (en) * 2007-11-30 2012-09-28 Glaxosmithkline Llc Benzopyrazine derivatives as prolyl hydroxylase inhibitors
JP2011505367A (ja) * 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
EP2273879A4 (en) 2008-04-30 2012-03-21 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
US20110077248A1 (en) 2008-05-29 2011-03-31 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
SG172206A1 (en) 2008-12-19 2011-07-28 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
SG178049A1 (en) * 2009-07-17 2012-03-29 Japan Tobacco Inc Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer

Also Published As

Publication number Publication date
SG178049A1 (en) 2012-03-29
KR20230165366A (ko) 2023-12-05
PL2455381T3 (pl) 2014-10-31
EP3594213A1 (en) 2020-01-15
PT2455381E (pt) 2014-06-24
ES2477968T9 (es) 2014-11-13
KR20180042443A (ko) 2018-04-25
SMT201500122B (it) 2015-07-09
JP2011037841A (ja) 2011-02-24
SI2455381T1 (sl) 2014-08-29
EP2455381B9 (en) 2014-10-22
CA2768505C (en) 2018-06-12
JP2024091878A (ja) 2024-07-05
EP2455381B1 (en) 2014-05-28
JP2016040321A (ja) 2016-03-24
PE20120629A1 (es) 2012-05-30
US8283465B2 (en) 2012-10-09
US20160145254A1 (en) 2016-05-26
JP6434575B2 (ja) 2018-12-05
ME01858B (me) 2014-12-20
KR20120051704A (ko) 2012-05-22
EP2746282A1 (en) 2014-06-25
RU2012105467A (ru) 2013-08-27
HK1168346A1 (en) 2012-12-28
US20110077267A1 (en) 2011-03-31
WO2011007856A1 (ja) 2011-01-20
AU2010271732B2 (en) 2016-08-25
JP2020111612A (ja) 2020-07-27
EP2455381A1 (en) 2012-05-23
IL217541A (en) 2014-07-31
RU2538963C2 (ru) 2015-01-10
JP2017214404A (ja) 2017-12-07
DK2455381T3 (da) 2014-07-21
JP2019019144A (ja) 2019-02-07
KR101850661B1 (ko) 2018-04-19
EP2455381A4 (en) 2012-12-12
AU2010271732A1 (en) 2012-03-08
KR20170018105A (ko) 2017-02-15
CN102471337B (zh) 2014-12-10
US20130096155A1 (en) 2013-04-18
KR101706803B1 (ko) 2017-02-14
HRP20140705T1 (hr) 2014-09-12
JP5021797B2 (ja) 2012-09-12
CO6430426A2 (es) 2012-04-30
ES2477968T3 (es) 2014-07-18
IL217541A0 (en) 2012-02-29
TWI485150B (zh) 2015-05-21
MY160814A (en) 2017-03-31
CA2768505A1 (en) 2011-01-20
JP2015003933A (ja) 2015-01-08
BR112012001157A2 (pt) 2016-02-23
JP2012144571A (ja) 2012-08-02
TW201105671A (en) 2011-02-16
NZ598242A (en) 2013-09-27
RS53499B1 (en) 2015-02-27
DK2455381T5 (en) 2015-02-09
JP2022126843A (ja) 2022-08-30
AR077417A1 (es) 2011-08-24
CN102471337A (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
MX2012000766A (es) Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
AU2012214029A8 (en) Rorgammat inhibitors
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
SG11201408052WA (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
WO2008011131A3 (en) Amide compounds
WO2008011130A8 (en) Amide compounds
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MX343740B (es) Derivados de bencilamina como inhibidores de calicreina plasmatica.
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
NZ600874A (en) Fluorinated derivatives of deferiprone
TN2012000092A1 (en) Therapeutic agent for mood disorders
IN2012DN01273A (es)
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
NZ596000A (en) Carboxamide compounds and their use as calpain inhibitors
WO2011050095A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.

Legal Events

Date Code Title Description
FG Grant or registration